London, UK; Brentwood, TN; 3 December 2007 - In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following: Protherics’ issued share capital consists of 339,950,033 ordinary shares with a nominal value of 2 pence each, with voting rights. Protherics does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in Protherics is 339,950,033.
